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ABSTRACT  
Worldwide, cancer is one of the leading causes of mortality and cancer rates are set to increase at alarming rate globally.  There are various 
types of cancer in which the leading type is the lung cancer.   In recent years lipid-based carriers, such as liposomes, have successfully 
encapsulated chemotherapeutic agents ameliorating some toxicity issues, while enhancing the overall therapeutic activity in cancer patients. In 
addition to this, nanomaterials can help to improved half-life in the body, morphology, for increased drug loading and many other ways. The 
survey discussed in this review will lead the anticancer therapy and cancer management which will provide the platform to the next generation.  
Therefore, this critical review includes the therapeutic interventions, liposomes target delivery, active and passive drug loading. Finally, we 
attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field.  
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1. INTRODUCTION 
According to the World Cancer Report, cancer rates could 
further increase by 50% to 15 million new cases in the year 
2020. The most prevalent types of cancer are prostate 
cancer and breast cancer in men and women, respectively. In 
addition, Lung cancer is the most frequent cause of death for 
both sexes. As evidenced by the high incidence and mortality 
rates, novel treatments strategies for this formidable disease 
are warranted. Cancer is a disease characterized by 
uncontrollable, irreversible, independent, autonomous, 
uncoordinated and relatively unlimited and abnormal over 
growth of tissues Figure 1. Cancer spreads by invasion to the 
surrounding tissues and by metastasis to distant sites. There 
are basically two types of cancer one is Benign tumors are 
not cancer: generally slow growing expansive masses often 
with a “Pushing margin” and enclosed within a fibrous 
capsule and another is Malignant tumors are cancer: usually 
rapidly growing, invading local tissue and spreading to 
distant sites. 
In all the types of cancer one of most leading cancer is lung 
cancer which is a commonest cancer caused due to tobacco 
smoke. It was in the observation that the more than 2 million 
peoples are affected by tobacco smoke in the world.  
Currently the intravenous administration of 
chemotherapeutic agents treatment is used as treatment of 
lung cancer. 
 
 
Figure 1 Process of cancer development  
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2. THERAPEUTIC INTERVENTIONS 
Most often cancer is treated with a myriad of therapeutic 
interventions including surgery, ionizing radiation and 
chemotherapy, the combination of which depends on the 
type and stage of disease. The goal of treatment is to reduce 
local tumor burden and eliminate all malignant cells. Surgery 
and radiation therapy are effective for local or contained 
disease, and is often curative at early stages of disease, but 
not all types of cancer can be treated by these methods. 
Treatment of main type of lung cancer which is non-small 
cell lung cancer/NSCLC generally requires partial surgery 
along with radiotherapy and chemotherapy. Both, radio and 
chemotherapy cause painful toxicity to the patient thereby 
requiring premature end of the therapy leaving the 
treatment halfway even though the tumor cells are 
successfully killed. The reason for this is that all cytotoxic 
drugs kill normal cells as well as cancerous cells resulting in 
severe side effects. Furthermore, because of the blood 
circulation in the body, only a small fraction of the drug 
actually reaches the target tumor tissue and most of the drug 
acts on normal tissues or is rapidly eliminated. Therefore, to 
obtain a therapeutic effect, a relatively high dose of drug 
must be administered and usual drug formulations are used 
in a balance between killing the tumor (efficacy) and killing 
the patient by causing lower toxicity to normal organs. The 
use of combination chemotherapy has been used in current 
treatment of NSCLC and is associated with a response rate of 
over 50% and a median survival of 8-12 months (1). This 
chemotherapy comprises only symptomatic management 
and partial cure. The major problems associated with 
chemotherapeutic agents are inadequate tumor specificity, 
narrow therapeutic indices and emergence of resistant 
cancer cells. Extensive side effects due chemotherapeutic 
anticancer drugs on normal dividing cells as hair follicles, 
germ cells and hematopoietic cells are well known resulting 
in dose limiting toxicity and incomplete therapy. 
The continual progress in survival outcomes and 
advancement in treatments have strongly paralleled the 
acquired scientific knowledge in tumor biology; and this is 
highlighted by the development of combination 
chemotherapy regimens that take into consideration 
mechanisms of drug action and developmental resistance 
(2). In addition, recent advances in research using liposomal 
and nanoparticulate systems in treatment of cancer have led 
to development of many products for more efficacious means 
of treating the lung cancer(3). Development of liposomal 
doxorubicin (DOXIL), daunorubicin, nanoparticulate 
paclitaxel (Abraxane), monoclonal antibody based Herceptin 
formulation have been the most successful and effective 
formulations or treatment of solid tumor and metastatic 
cancer with higher selectivity at site of cancer and lower 
systemic side effects. However, direct targeting of these 
drugs to the lung tissue without systemic side-effects has still 
been a mystery without any suitable treatment solution. 
3. DRUG DELIVERY BASED ON LIPOSOMES 
Antineoplastic agents used in the treatment of lung cancer 
have often associated with number of severe toxicities such 
as bone marrow depression results in granulocytopenia, 
agranulocytosis, thrombocytopenia, and aplastic anemia, 
lymphocytopenia and inhibition of lymphocyte function 
results in suppression of host immunity etc. Currently 
Paclitaxel, Carboplatin, Cisplatin, Docetaxel, Topotecan, 
Etoposide, Gemcitabine are the most widely used anticancer 
agents in treatment of lung cancer with their known 
reported toxicities. The medications are available as 
injections for systemic use and result in hazardous side 
effects due to their non-specificity on the dividing cells in the 
body.  Intracellular transport of different biologically active 
molecules is one of the key problems in drug delivery in 
general. Currently the anticancer agents have poor 
intracellular concentration in the cancer cells. 
In view of the light of above facts associated with many of the 
available chemotherapeutic agents, drug delivery systems 
have been used as one of the promising strategies to improve 
pharmacological effects of these drugs. Amongst the many 
delivery systems designed for intravenous use such as 
micelles, lipid emulsions, liposomes, polymer-drug 
conjugates, polymer microspheres, nanoparticles, niosomes, 
and osmotic pumps, liposome technology has been 
successful with several products currently available for 
human use. 
3.1 Liposomes as Drug Carrier 
The use of liposomes as drug delivery agents has evolved 
from a line of research originating over 40 years ago, based 
on the ability of these unilamellar vesicles to entrap material 
in an aqueous compartment (4). It was then known that most 
amphipathic membrane lipids form multilamellar vesicles 
(MLV) consisting of concentric bilayers when they are 
dispersed in aqueous media. MLV are relatively large 
(micron) sized structures, however they can be extruded 
through 100 nm pore size polycarbonate filters to produce 
unilamellar vesicles with a homogeneous size distribution 
(5),(6). Typically, the resulting liposomes are 100 nm in 
diameter and each particle contains numerous lipid 
molecules (2). Liposomes have been widely used as models 
of biological membranes to study membrane permeability 
and transport across the bilayer (7). In addition to their 
utility as model membranes, drugs may be encapsulated 
within their interior aqueous compartment(8).  The ability of 
liposomes to deliver drugs preferentially to disease sites, 
such as solid tumors, can result in considerable 
improvements in efficacy; therefore, liposomes are widely 
studied for use in therapeutic applications Figure 2. 
 
 
Figure 2: Types of Liposome for drug Delivery 
The first preparation of a liposome with entrapped solute 
was characterized in 1965 by A. D. Bangham in Cambridge, 
UK (4). The evolution of liposomes as drug delivery systems 
was subsequently accelerated in the 1980,s by the 
Patel et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):367-370 
ISSN: 2250-1177                                                                                  [369]                                                                                 CODEN (USA): JDDTAO 
development of techniques to rapidly generate well defined 
liposomal systems and to efficiently load them with drugs 
(9),(10). The observation that long-circulating liposomes 
preferentially accumulate at sites of disease, including sites 
of infection, inflammation and tumors, due to the leaky 
nature of the vasculature in these regions(11), (12) gave a 
solid rationale for delivering drugs in liposomal systems. 
Liposomes have several features that have contributed to 
their success as a drug delivery system. Encapsulation 
within the aqueous cavity of an liposomes can enhance the 
in vivo activity of drugs by protecting them from breakdown 
in the body and can reduce the toxic effects of drugs, such as 
anti-cancer drugs, by reducing delivery to sensitive tissue 
(13). 
3.2 Liposomes for Targeted Drug Therapy 
The concept of site specific drug delivery for treatment of 
localized disease in the body to improve therapeutic index of 
the drug is considered as perennial challenge to the 
formulator in modern formulation design(14). Constant 
efforts have been pursued in designing such an ideal drug 
delivery system which can effectively overcome dose related 
toxicity and adverse side effects and thus improve patient 
compliance. One such area which has attracted ever growing 
attention of pharmaceutical scientist and has shown 
tremendous potential and promise is colloidal drug carrier 
system (15). The idea of drug carrier with targeted 
specificity has fascinated scientists for number of years and 
in the last decade successful efforts have been made to 
achieve this goal. The ultimate form of targeted drug 
delivery system should be realization of Paul Ehrlichs “magic 
bullet concept” (16) which documents the delivery of drug 
exclusively to a preselected targeted cell type. Amongst all 
targeted drug delivery systems, Liposomes are recently 
gaining popularity because of their biological inert nature, 
freedom from antigenic, pyrogenic or allergic reaction and 
their enhanced stability (17). 
The development of liposomes containing lipid derivatives 
of PEG or saturated phospholipids such as DSPC with 
cholesterol has made targeted liposomal therapy more 
feasible by reducing the uptake by the RES system and there 
by prolonging the circulation time.Particularly, PEG is useful 
because of its ease of preparation, relatively low cost, 
controllability of molecular weight and linking ability to 
lipids or peptide including RGD peptide by a variety of 
methods. The presence of PEG reduces binding of serum 
protein, i.e. opsonins marking the liposome for clearance by 
macrophages (18).  
Targeting using small peptides like RGD has certain 
advantages over the use of conventional protein 
macromolecules. These include ease of preparation, lower 
antigenicity, and increased stability (19). Antineoplastic 
agents used in the treatment of lung cancer, solid tumor, 
testicular cancer, breast cancer, several types of leukemia, 
lymphoma and etc. have often associated with number of 
severe toxicities such as bone marrow depression results in 
granulocytopenia, agranulocytosis, thrombocytopenia, and 
aplastic anemia, lymphocytopenia and inhibition of 
lymphocyte function results in suppression of host immunity 
(20). 
3.3 Drug Loading in Liposomes 
In the early 1970s, it was proposed that liposomes could 
potentially hold entrapped pharmaceuticals for treatment of 
diseases. Within this review two anti-cancer drugs, were 
encapsulated in liposomes. The advantages and 
disadvantages of different loading methods used to 
encapsulate these drugs will be discussed below. 
3.3.1 Passive Loading 
Hydrophobic drugs (e.g., taxol and amphotericin B) or water 
soluble drugs (e.g., cytarabine and gemcitabine) may be 
passively entrapped within liposomes during hydration of 
lipid and liposome formation. Encapsulation efficiencies up 
to 100% may be achieved for hydrophobic drugs when 
exhibiting favorable drug-lipid interactions and drug 
solubility. Passive loading of water soluble drugs is typically 
very low (<30%) and is dependent on the trapped volume of 
the liposome and liposomal lipid concentration. If drugs 
have to be encapsulated using passive loading methods it is 
more difficult to control parameters such as drug-to-lipid 
ratios and trapping efficiency. In the case of cytotoxic drugs, 
passive trapping also means that careful methods must be in 
place during liposome preparation and following 
preparation to remove the unencapsulated drug. 
3.3.2 Remote Loading 
Drugs, such as anthracycline antibiotics, can alternatively be 
loaded into preformed liposomes containing a pH gradient 
(pH 4.0 inside, pH 7.4 outside). This method is limited to 
drugs having an ionizable amine function, and results in 
encapsulation efficiencies of less than 98%. For 
anthracyclines, the encapsulation efficiencies are much 
higher than predicted by the Henderson-Hasselbach 
equation, and may be explained by the formation of drug 
micro precipitates and/or drug association with or 
partitioning into the lipid membrane. Drug retention by this 
method is dependent on liposome composition including 
surface charge, phospholipid acyl chain length, cholesterol 
content, internal buffering capacity, drugto- lipid ratio, pH 
gradient, and liposome size parameters that can all be 
independently altered. Other active loading methodologies 
include the ammonium sulfate gradient 
methodand metal complexation. The latter is of potential 
interest since drug loading may not be dependent on 
maintenance of an established pH gradient. 
CHALLENGES TO DRUG DELIVERY TO SOLID 
TUMORS 
The term "tumor" (neoplasm) refers to a collection of 
abnormally growing cells which is not always synonymous 
with cancer. Some tumors are benign (non-cancerous) while 
others are malignant (cancerous). The term solid tumor is 
used to distinguish between a localized solid mass of tissue 
and leukemia. Leukemia is a type of cancer that is defined by 
abnormal increase in the number of leukocytes and since it 
affects the blood, it takes on fluid properties. Malignant 
tumors differ from benign ones in that they are capable of 
spreading into surrounding tissues (invasion) and 
transferring to other organs or parts of the body that are not 
directly in contact with the malignant tumor through blood 
circulation and/or lymphatic system (metastasis). Tumors 
tend to grow exponentially; a single tumor cell can produce a 
one-gram tumor (10 to 10 cells) after about 30 doublings in 
volume, and with another 10 doublings in volume it would 
produce a very large tumor of about one kilogram (21),(22). 
Over 85% of the human cancers are solid tumors (23). 
An elevated interstitial pressure further limits drug diffusion 
into distant tumor cells (24). The center of the tumor has 
high interstitial pressure. This elevated pressure in the inner 
zone can impede movement of drug molecules into the 
tumor matrix. 6. In addition, rapidly proliferating cancer 
cells easily undergo treatment resistant mutations and are 
known to develop, so called, 'multi drug resistance, very 
soon. Development of this drug resistance is probably 
through generation of drug exporters in these tumor cells 
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(25). Metastasis of these cancerous cells spreads the disease 
to other tissues as well. These limitations virtually restrict 
our ability to kill the solid tumor cancer cells per se with the 
available cytotoxic drugs; therefore, the actual target has to 
be redefined. Recently, vasculature targeting has been 
proposed to be a promising alternative for effective solid 
tumor treatment (26). This approach involves killing tumor 
cells by denying them of their life blood. This strategy may 
involve anti-angiogenesis-inhibition of new blood vessel 
formation, or anti-vascular approaches that aim to cause a 
rapid and extensive shutdown of the established tumor 
vasculature leading to secondary tumor cell death. The 
functioning vascular network in tumors provides the tumor 
cells with oxygen and nutrients and enables removal of the 
toxic waste products of cellular metabolism and as such, it is 
pivotal for the survival of the tumor cells. Disruption of this 
vasculature results in tumor cell death and consequently 
tumor cures. Malignant cells, like normal mammalian cells 
require oxygen and nutrients for their survival and are, 
therefore, located in near area.  
For tumors to grow beyond this size, they must recruit new 
blood vessels by vasculogenesis and angiogenesis. Without 
blood vessels, tumors cannot grow beyond a critical size and 
cannot metastasize to another organ (27). Considering the 
limitations of existing solid tumor cancer therapy, anti-
vascular therapy using solid tumor vasculature targeting 
appears to be an attractive strategy. 
CONCLUSION  
Cancer is the deadliest disease and effective treatment to 
solid tumor such as lung cancer is very challenging. Though 
there are anti-cancer drugs available for better therapy, 
there is a need to have a promising drug delivery system 
which can reduce the side effects and improve the therapy 
outcome. Liposomes are such drug delivery vesicles in which 
variety of drugs can be loaded and can be delivered at the 
tumor site. Researchers are designing liposomal delivery 
systems to deliver various classes of drugs for the cancer 
treatment and that has a commercial application too. To 
conclude, a lot of research have been done in studying 
liposomes as a drug carrier for cancer therapy and may 
serve as an upcoming strategy for efficient treatment of lung 
cancer. 
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